Alle Storys
Keine Story von Eisai Co. Ltd. mehr verpassen.

Eisai Co. Ltd.

Eisai Announce Establishment of New Pharmaceutical Marketing Subsidiary in Belgium

London (ots/PRNewswire)

- For the Attention of Business and Healthcare Editors
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo
Naito) announced today that the Company established its
pharmaceutical marketing subsidiary, Eisai SA/NV in Belgium. Eisai
SA/NV is owned by Eisai Europe Limited (Headquarters: London,
President: Yutaka Tsuchiya).
Serving as the regional sales hub for Benelux (Belgium,
Netherlands and Luxembourg), which is the sixth largest market in the
EU, Eisai SA/NV will start marketing activities in all three Benelux
countries in due course with the focus on the anti-epileptic drugs
Zonegran(R) and Inovelon(R), as well as the non-opioid severe chronic
pain agent Prialt(R). In addition, Eisai SA/NV plans to start
promotion of its Alzheimer's disease treatment Aricept(R) in Belgium
and Luxembourg with its co-promotion partner.
Eisai plans further expansion of its business operations across
Europe and will undertake "Independent Marketing" activities by using
their own sales and marketing personnel, tailored for each county.
Eisai SA/NV is the Company's ninth marketing subsidiary in Europe,
and brings the total number of countries where Eisai undertake sales
and marketing operations through its own distribution channels to 17,
including; the United Kingdom, France, Germany, Italy, Spain,
Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway,
Portugal, Iceland, Belgium, Netherlands, and Luxembourg.
Through stable provision of Eisai's products, further enabled by
the establishment of new subsidiaries and branches, Eisai is
committed to increasing patient value and fulfilling the diverse
needs of patients and their families throughout Europe.
    Company Outline
    Company Name: Eisai SA/NV
    Establishment Date: September 10, 2007 (Local Time)
    Capital: EUR7 million (approx. 1,100 million yen)
    Location: Brussels, Belgium
    Operations: Promoting the sale of pharmaceutical products


For further information contact: Andrew Day, Eisai Europe Corporate
Affairs Department, +44-(0)208-600-1400,

Weitere Storys: Eisai Co. Ltd.
Weitere Storys: Eisai Co. Ltd.
  • 15.05.2007 – 12:20

    Eisai Signs Exclusive Agreement to Commercialize NeuroBloc(R) for Europe

    Tokyo (ots/PRNewswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced that the company has signed on May 14, 2007 (the U.S. Eastern Time) the exclusive agreement with Solstice Neurosciences, Inc. (Headquarters: Pennsylvania, U.S., President & CEO: Shawn Patrick O'Brien) for NeuroBloc(R) , an injectable form of botulinum toxin ...

  • 22.03.2007 – 16:57

    Eisai to Acquire Morphotek

    Tokyo, Japan, Woodcliff Lake, New Jersey and Exton, Pennsylvania (ots/PRNewswire) - - Eisai's Dramatic Leap Towards Biologic Therapeutics Evidenced by the Acquisition Eisai Co., Ltd. (Tokyo, "Eisai", President and CEO: Haruo Naito), Eisai Corporation of North America (Woodcliff Lake, NJ, "ECA", President: Hajime Shimizu) and Morphotek(R) Inc. (Exton, PA, "Morphotek", CEO: Nicholas Nicolaides) today announce that ECA has signed a definitive agreement to acquire ...

  • 16.03.2006 – 07:04

    Eisai Reports Results from Latest Donepezil Study in Vascular Dementia

    Tokyo, Japan (ots/PRNewswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) today announced preliminary results from the latest donepezil (Product name: ARICEPT(R)) study (Study 319) on the treatment of people with vascular dementia (VaD). Preliminary efficacy results show that those who received donepezil improved on measures of cognition, ...